Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 01, 2024

SELL
$0.41 - $0.86 $2,050 - $4,300
-5,000 Reduced 29.41%
12,000 $10,000
Q2 2023

Aug 01, 2023

SELL
$0.54 - $0.95 $21,870 - $38,475
-40,500 Reduced 70.43%
17,000 $9,000
Q1 2022

Apr 20, 2022

BUY
$1.23 - $1.9 $17,835 - $27,550
14,500 Added 33.72%
57,500 $102,000
Q4 2021

Feb 02, 2022

BUY
$1.64 - $2.83 $70,520 - $121,690
43,000 New
43,000 $80,000

Others Institutions Holding MBRX

About Moleculin Biotech, Inc.


  • Ticker MBRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,606,700
  • Market Cap $48.6M
  • Description
  • Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs....
More about MBRX
Track This Portfolio

Track Sigma Planning Corp Portfolio

Follow Sigma Planning Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sigma Planning Corp, based on Form 13F filings with the SEC.

News

Stay updated on Sigma Planning Corp with notifications on news.